Skye Bioscience (SKYE) News Today $1.70 -0.03 (-1.45%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Weiss Ratings Reaffirms "Sell (D-)" Rating for Skye Bioscience (NASDAQ:SKYE)October 9 at 2:39 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYEOctober 8 at 5:45 PM | prnewswire.comSkye Bioscience (NASDAQ:SKYE) Stock Rating Lowered by Cantor FitzgeraldOctober 8 at 2:51 AM | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Stock Rating Lowered by Craig HallumOctober 8 at 2:17 AM | americanbankingnews.comWhy Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's NextOctober 7 at 1:05 PM | finance.yahoo.comSkye’s shares crash down to earth on Phase II obesity lossOctober 7 at 8:04 AM | finance.yahoo.comSkye's obesity drug misses mid-stage trial main goal, shares tankOctober 6 at 11:18 PM | msn.comSkye Bioscience Shares Plunge After Weight Loss Drug Fails Mid-Stage TrialOctober 6 at 11:18 PM | msn.comSkye Bioscience, Inc. - Special CallOctober 6 at 3:13 PM | seekingalpha.comCraig Hallum Downgrades Skye Bioscience (NASDAQ:SKYE) to HoldOctober 6 at 1:23 PM | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Lowered to "Neutral" Rating by Cantor FitzgeraldOctober 6 at 11:17 AM | marketbeat.comSkye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight LossOctober 6 at 11:03 AM | benzinga.comSkye Bioscience stock plummets after failed weight loss drug trialOctober 6 at 9:25 AM | investing.comSkye Bioscience Shares Slide as Weight-Loss Drug Candidate Misses Primary EndpointOctober 6 at 9:25 AM | marketwatch.comWhy Did Skye Bioscience Stock Plummet A Whopping 60% Today?October 6 at 9:25 AM | msn.comSkye Bioscience's obesity drug fails to meet main goal of mid-stage studyOctober 6 at 7:09 AM | reuters.comSkye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical TrialOctober 6 at 7:00 AM | globenewswire.comHC Wainwright Forecasts Skye Bioscience Q3 EarningsOctober 4, 2025 | americanbankingnews.comHC Wainwright Weighs in on Skye Bioscience Q3 EarningsOctober 2, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Skye Bioscience (SKYE) with Buy RecommendationOctober 1, 2025 | msn.comSkye Bioscience: Promising Nimacimab Data Supports Buy RatingOctober 1, 2025 | seekingalpha.comSkye Bioscience initiated with a Buy at H.C. WainwrightSeptember 30, 2025 | msn.comHC Wainwright Initiates Coverage on Skye Bioscience (NASDAQ:SKYE)September 30, 2025 | marketbeat.comSkye Bioscience presents Phase 1b data from nimacimab studySeptember 20, 2025 | msn.comCould This New Drug Be The Safer Way To Fight Obesity?September 19, 2025 | benzinga.comSkye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual MeetingSeptember 19, 2025 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 17, 2025 | marketbeat.comSkye Bioscience (SKYE) Receives a Buy from Citizens JMPSeptember 12, 2025 | theglobeandmail.comCantor Fitzgerald Sticks to Its Buy Rating for Skye Bioscience (SKYE)September 12, 2025 | theglobeandmail.comSkye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comSkye Bioscience (SKYE) Gets a Buy from Craig-HallumSeptember 6, 2025 | theglobeandmail.comSkye Bioscience Advances Position In Competitive Obesity Market With Promising DataSeptember 5, 2025 | benzinga.comSkye Bioscience reports results from two preclinical DIO studies on nimacimabSeptember 4, 2025 | msn.comSkye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide ...September 4, 2025 | theglobeandmail.comSkye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO ModelSeptember 4, 2025 | globenewswire.comSkye Completes 26-week Treatment Phase in Phase 2a CBeyond™ StudySeptember 3, 2025 | markets.businessinsider.comSkye Bioscience, Inc.: Skye Completes 26-week Treatment Phase in Phase 2a CBeyond StudySeptember 2, 2025 | finanznachrichten.deSkye Completes 26-week Treatment Phase in Phase 2a CBeyond™ StudySeptember 2, 2025 | globenewswire.comSkye Bioscience to host KOL event on CBeyond Phase 2a clinical data readoutAugust 27, 2025 | msn.comSkye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data ReadoutAugust 27, 2025 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by AnalystsAugust 24, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Major Shareholder 5Am Partners Vii, Llc Sells 60,956 SharesAugust 23, 2025 | insidertrades.comSkye Bioscience, Inc. to Present at Multiple Investment and Medical Conferences in September 2025August 21, 2025 | quiverquant.comQSkye Bioscience to Participate in Upcoming Investment and Medical ConferencesAugust 21, 2025 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Upgraded by Evercore ISI to Strong-Buy RatingAugust 18, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform RecommendationAugust 16, 2025 | msn.comEvercore starts Skye Bioscience at Outperform on nimacimab potentialAugust 14, 2025 | msn.comSkye Bioscience initiated with an Outperform at Evercore ISIAugust 14, 2025 | msn.comSkye Bioscience, Inc. (NASDAQ:SKYE) is Altium Capital Management LLC's 9th Largest PositionAugust 14, 2025 | marketbeat.comSkye Bioscience Earnings Call: Positive Outlook Amid ChallengesAugust 13, 2025 | msn.com Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SKYE Media Mentions By Week SKYE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SKYE News Sentiment▼0.090.63▲Average Medical News Sentiment SKYE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SKYE Articles This Week▼303▲SKYE Articles Average Week Get the Latest News and Ratings for SKYE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Skye Bioscience and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CMPX News SLDB News OCGN News CYRX News MLTX News GLUE News ADCT News KRRO News PRTC News AUTL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SKYE) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
